US2002091086A1PendingUtilityA1
Peptides that block viral infectivity and methods of use thereof
Priority: Aug 9, 1999Filed: Apr 6, 2001Published: Jul 11, 2002
Est. expiryAug 9, 2019(expired)· nominal 20-yr term from priority
Inventors:Anders Vahlne
A61P 31/00A61P 31/18A61P 31/12Y10S977/916C12N 2740/15022C12N 2740/16122C07K 14/005A61K 38/00C07K 5/08
45
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The discovery of peptides in amide form that inhibit viral infection, including human immunodeficiency virus (HIV) infection is disclosed. Methods of use of peptides are also disclosed including use in medicaments for the treatment and prevention of viral infection, such as HIV infection.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of inhibiting propagation of a virus in a host cell comprising:
providing said cell with an effective amount of a tripeptide in amide form consisting of the formula X 1 X 2 X 3 -NH 2 , wherein X 1 , X 2 , and X 3 are any amino acid, wherein said tripeptide is not Gly-Pro-Gly-NH 2 , and wherein said tripeptide has a sequence that corresponds to a sequence of a capsid protein of said virus.
2 . The method of claim 1 , wherein said virus is a retrovirus.
3 . The method of claim 1 , wherein said virus is a lentivirus.
4 . The method of claim 3 , wherein said virus is HIV.
5 . The method of claim 4 , wherein said tripeptide is Gly-Lys-Gly-NH 2
6 . The method of claim 4 , wherein said tripeptide is Arg-Gln-Gly-NH 2
7 . The method of claim 4 , wherein said tripeptide is Cys-Gln-Gly-NH 2 .
8 . The method of claim 4 , wherein said tripeptide is Lys-Gln-Gly-NH 2
9 . The method of claim 4 , wherein said tripeptide is Ala-Leu-Gly-NH 2 .
10 . The method of claim 4 , wherein said tripeptide is Gly-Val-Gly-NH 2
11 . The method of claim 4 , wherein said tripeptide is Val-Gly-Gly-NH 2
12 . The method of claim 4 , wherein said tripeptide is Ala-Ser-Gly-NH 2
13 . The method of claim 4 , wherein said tripeptide is Ser-Leu-Gly-NH 2
14 . The method of claim 4 , wherein said tripeptide is Ser-Pro-Thr-NH 2 .
15 . The method of claim 1 , further compri sin g providing to said cell an antiviral treatment selected from the group consisting of nucleoside analogue reverse transcriptase inhibitors, nucleotide analogue reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors.
16 . The method of claim 1 , wherein said tripeptide is joined to a support.
17 . The method of claim 1 , wherein said tripeptide is provid ed to said cell in combination with a pharmaceutically acceptable carrier.
18 . A method of identifying a tripeptide in amide form for incorporation into an anti-viral pharmaceutical comprising:
(a) selecting a tripeptide sequence that corresponds to a capsid sequence of a virus; (b) providing a tripeptide in amide form consisting of said tripeptide; (c) contacting a plurality of cells infected with said virus with an effective amount of said tripeptide; and (d) determining whether said contacting results in inhibition of propagation of said virus.
19 . The method of claim 18 , wherein said virus is a retrovirus.
20 . The method of claim 18 , wherein said virus is a lentivirus.
21 . The method of claim 18 , wherein said virus is HIV.
22 . A method of inhibiting propagation of HIV in a human comprising:
identifying a human in need of a medicament that inhibits propagation of HIV; and providing to said human an effective amount of a tripeptide in amide form consisting of the formula X 1 X 2 X 3 -NH 2 , wherein X 1 , X 2 , and X 3 are any amino acid, wherein said tripeptide is not Gly-Pro-Gly-NH 2 , and wherein said tripeptide has a sequence that corresponds to a sequence of p24.
23 . The method of claim 22 , wherein said tripeptide is Gly-Lys-Gly-NH 2
24 . The method of claim 22 , wherein said tripeptide is Arg-Gln-Gly-NH 2
25 . The method of claim 22 , wherein said tripeptide is Cys-Gln-Gly-NH 2 .
26 . The method of claim 22 , wherein said tripeptide is Lys-Gln-Gly-NH 2
27 . The method of claim 22 , wherein said tripeptide is Ala-Leu-Gly-NH 2 .
28 . The method of claim 22 , wherein said tripeptide is Gly-Val-Gly-NH 2 .
29 . The method of claim 22 , wherein said tripeptide is Val-Gly-Gly-NH 2 .
30 . The method of claim 22 , wherein said tripeptide is Ala-Ser-Gly-NH 2 .
31 . The method of claim 22 , wherein said tripeptide is Ser-Leu-Gly-NH 2 .
32 . The method of claim 22 , wherein said tripeptide is Ser-Pro-Thr-NH 2 .
33 . The method of claim 22 , further comprising providing to said human an antiviral treatment selected from the group consisting of nucleoside analogue reverse transcriptase inhibitors, nucleotide analogue reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors.
34 . The method of claim 22 , wherein said tripeptide is joined to a support.
35 . The method of claim 22 , wherein said tripeptide is provided to said human in combination with a pharmaceutically acceptable carrier.
36 . The method of claim 22 , wherein said tripeptide is provided to said human topically.
37 . The method of claim 22 , wherein said tripeptide is provided to said human transdermally.
38 . The method of claim 22 , wherein said tripeptide is provided to said human parenterally.
39 . The method of claim 22 , wherein said tripeptide is provided to said human gastrointestinally.
40 . The method of claim 22 , wherein said tripeptide is provided to said human transbronchially.
41 . The method of claim 22 , wherein said tripeptide is provided to said human transalveolarly.Join the waitlist — get patent alerts
Track US2002091086A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.